Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)

Inclusion Criteria:

- Have documented or anticipated neutropenia expected to last for at least 7 days,
following treatment in at least one of the following clinical situations: acute
leukemia, myelodysplasia, severe aplastic anemia, recipients of Autologous
hematopoietic stem cell transplant (HSCT), high risk neuroblastoma, advanced stage
non-Hodgkin's lymphoma, hemophagocytic lymphohistiocytosis

- Have a central line in place prior to IV study therapy

- Participants of reproductive potential agree to remain abstinent, or use a medically
accepted method of birth control

Exclusion Criteria:

- Has a proven or probable invasive fungal infection

- Has received any formulation of POS within prior 10 days

- Is receiving any prohibited drugs

- Has laboratory results that are outside of normal limits at screening, as follows: a)
Moderate or severe liver dysfunction, as defined as: Aspartate aminotransferase (AST)
> 5 times the upper limit of normal (ULN), OR Alanine aminotransferase (ALT) > 5 times
the ULN, OR Serum total bilirubin >2.5 times the ULN, OR AST or ALT > 3 times ULN with
total bilirubin > 2 times ULN; b) Calculated creatinine clearance <30 mL/min.

- Has QTc (QT interval corrected for rate) prolongation defined as: a) Symptomatic QTc
prolongation >450 msec (males) or >470 msec (females) OR b) Any QTc prolongation of
>500 msec

- Is pregnant, intends to become pregnant during study, or is breastfeeding

- Has a history of anaphylaxis attributed to the azole class of antifungal agents

- Is not expected to receive a minimum of 10 days of POS IV solution

- Has participated in any Phase 1 Investigational New Drug (IND) study within prior 30
days or expects to do so within the following 60 days

- Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or
child) who is investigational site or sponsor staff directly involved with this trial.